The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Cytarabine and neurologic toxicity.
Abstract
Cytarabine is an effective drug in the treatment of certain hematologic malignancies and its common toxicities are myelosuppression and gastrointestinal disturbance. In the past decade, neurotoxicity has been an increasingly recognized cytarabine effect. Intrathecal (IT) cytarabine may result in myelopathy that is incompletely reversible. Combined IT drug and cranial irradiation may lead to necrotizing leukoencephalopathy. Intravenous (IV) therapy may cause a peripheral neuropathy that varies greatly in its severity. The high IV cytarabine doses now commonly used can cause seizures, cerebral dysfunction, or an acute cerebellar syndrome with an incidence up to 14%. Patient age (greater than 60 years) appears to be the most important risk factor, but drug dose/schedule, cumulative drug dose, renal and hepatic dysfunction, and concomitant use of neurotropic antiemetic agents may also influence the risk of neurotoxicity. A better understanding of the pathophysiology and pharmacology of such cytarabine-induced neuronal injury will allow this drug to be used with greater efficacy and safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arabinosyl Cytosine: A Useful Agent in the Treatment of Acute Leukemia in Adults
ELLISON, R. R., HOLLAND, J. F., WEIL, M., JACQUILLAT, C., BOIRON, M., BERNARD, J., SAWITSKY, A., ROSNER, F., GUSSOFF, B., SILVER, R. T., et al. (1968) · Blood · doi:10.1182/blood.v32.4.507.507 · Cited by 549
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B
Rai, K., Holland, J., Glidewell, O., Weinberg, V, Brunner, K., Obrecht, J., Preisler, H., Nawabi, I., Prager, D., Carey, R., et al. (1981) · Blood · doi:10.1182/blood.v58.6.1203.1203 · Cited by 532
Bergmann (1951) · doi:10.1021/jo01146a023 · Cited by 403
High-dose cytosine arabinoside therapy for refractory leukemia
Herzig, R., Wolff, S., Lazarus, H., Phillips, G., Karanes, C., & Herzig, G. (1983) · Blood · doi:10.1182/blood.v62.2.361.361 · Cited by 372
Possible involvement of GABA in the central actions of benzodiazepines.
Haefely, W. E., Kulcsár, A., Möhler, H., Pieri, L., Polc, P., & Schaffner, R. (1975) · PubMed · Cited by 357
Neurotoxicity and Elevated Cerebrospinal-Fluid Methotrexate Concentration in Meningeal Leukemia
Bleyer, W. A., Drake, J. C., & Chabner, B. A. (1973) · New England Journal of Medicine · doi:10.1056/nejm197310112891503 · Cited by 337
Preisler, H. D., Davis, R., Kirshner, J. J., Dupre, E., Richards, F., Hoagland, H. C., Kopel, S., Levy, R., Carey, R. W., & Schulman, P. (1987) · PubMed · doi:10.1182/blood.v69.5.1441.1441 · Cited by 294
Autoradiographic localisation of benzodiazepine receptors in the brains of humans and animals
YOUNG, W. S., & KUHAR, M. J. (1979) · Nature · doi:10.1038/280393a0 · Cited by 257
He, S., Fm, S., & Wilcox, W. S. (1967) · PubMed · Cited by 233
Cytosine Arabinoside Influx and Nucleoside Transport Sites in Acute Leukemia
Wiley, J. S., Jones, S. P., Sawyer, W. H., & Paterson, A. R. P. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110472 · Cited by 212
Rustum, Y. M., & Preisler, H. D. (1979) · PubMed · Cited by 185
Cerebellar toxicity with high-dose cytosine arabinoside.
Herzig, R. H., Hines, J. D., Herzig, G. P., Wolff, S. N., Cassileth, P. A., Lazarus, H. M., Adelstein, D. J., Brown, R. A., Coccia, P. F., & Strandjord, S. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.6.927 · Cited by 162
Wolff, S. N., Herzig, R. H., Fay, J. W. J., Phillips, G. L., Lazarus, H. M., Flexner, J. M., Stein, R. S., Greer, J. P., Cooper, B., & Herzig, G. P. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1260 · Cited by 143
Cytosine arabinoside cerebrospinal fluid kinetics
Zimm, S., Collins, J. M., Miser, J. S., Chatterji, D. C., & Poplack, D. G. (1984) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1984.120 · Cited by 142
Pharmacokinetics and metabolism of cytosine arabinoside in the central nervous system.
Spector, R. (1982) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33144-7 · Cited by 114
Effects of 1-beta-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function.
Kufe, D. W., Munroe, D. G., Herrick, D., Egan, E. M., & Spriggs, D. R. (1984) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)15031-1 · Cited by 111
Central nervous system toxicity with high‐dose Ara‐C
Hwang, T.-L., Yung, W. K. A., Estey, E. H., & Fields, W. S. (1985) · Neurology · doi:10.1212/wnl.35.10.1475 · Cited by 99
Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C)
Breithaupt, H., Pralle, H., Eckhardt, T., Hattingberg, M., Schick, J., & Löffler, H. (1982) · Cancer · Cited by 78
Neurotoxicity associated with systemic high-dose cytosine arabinoside.
Nand, S., Messmore, H. L., Patel, R., Fisher, S. G., & Fisher, R. I. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.4.571 · Cited by 72
The association between high-dose cytarabine neurotoxicity and renal insufficiency.
Damon, L. E., MASS, R. D., & Linker, C. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1563 · Cited by 60
Cytosine arabinoside in acute granulocytic leukemia
Goodell, B. W., Leventhal, B. G., & Henderson, E. S. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971124599 · Cited by 55
Burch, P. A., Grossman, S. A., & Reinhard, C. S. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.15.1211 · Cited by 54
Cerebellar toxicity following high-dose cytosine arabinoside.
Dworkin, L. A., Goldman, R. D., Zivin, L. S., & Fuchs, P. C. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.5.613 · Cited by 47
ADLARD, B. P. F., Dobbing, J., & Sands, J. (1975) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1975.tb07406.x · Cited by 45
Brachial plexus neuropathy following high-dose cytarabine in acute monoblastic leukemia.
Scherokman, B., Filling‐Katz, M. R., & Tell, D. (1985) · PubMed · Cited by 29
Drug‐Induced Toxicities Associated with High‐Dose Cytosine Arabinoside Infusions
Graves, T., & Hooks, M. A. (1989) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1989.tb04099.x · Cited by 19
Patel, A. J., Hunt, A., & Seaton, P. (1988) · Brain Research · doi:10.1016/0006-8993(88)91579-x · Cited by 16
Neuroanatomical study of somatomotor cortex in microcephalic mice induced by cytosine arabinoside
Ohno, M. (1984) · Brain and Development · doi:10.1016/s0387-7604(84)80096-0 · Cited by 9
Cited by
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Nucleoside analogues and nucleobases in cancer treatment
Galmarini, C. M., Mackey, J. R., & Dumontet, C. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00788-x · Cited by 606
Nucleoside analogues: mechanisms of drug resistance and reversal strategies
Galmarini, C., Mackey, Jr., & Dumontet, C. (2001) · Leukemia · doi:10.1038/sj.leu.2402114 · Cited by 511
Dietrich, J., Han, R., Yang, Y., Mayer-Pröschel, M., & Noble, M. (2006) · Journal of Biology · doi:10.1186/jbiol50 · Cited by 500
Metadata
- Authors
- Baker, W. J., Royer, G. L., & Weiss, R. B.
- Venue
- Journal of Clinical Oncology
- Published
- 1991-04
- Volume
- 9
- Issue
- 4
- Pages
- 679-693
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1828655749
- Cited by
- 285
- References
- 28
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.